Contact Congress about S. 1784: MAPS Act
The bill would make the government map supply chains for key medicines. Agencies would look for shortage risks, foreign dependence, cyber threats, and drugs tied to China. Congress would get regular reports, and the public would get some results.
Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
MAPS Act is a Senate bill in committee. The latest recorded action: Committee on Health, Education, Labor, and Pensions. Hearings held.
Latest action on S. 1784: Committee on Health, Education, Labor, and Pensions. Hearings held.
Who this affects: This bill mainly affects patients, hospitals, pharmacies, drug makers, federal health agencies, and the military. Patients and health systems could benefit if the government spots shortages earlier. Drug makers may face more requests for supply chain data. Defense officials would get more information about whether military medicine supplies depend on China or other risky sources.
Why this matters: Medicine shortages can hurt patients and weaken military readiness, and the government may not always know where the weak points are. This bill would create a clearer map of where essential medicines and their ingredients come from. It could help agencies spot risks from foreign suppliers, cyberattacks, factory problems, or global conflict. The bill does not itself fix those risks, so later action would still matter.
Key provisions in S. 1784
- Health and Human Services must keep a public Essential Medicines List. It must update the list at least every two years, with the first update due 180 days after the bill becomes law.
- The list must cover medicines needed for major threats and urgent care. That includes chemical, biological, radiological, and nuclear threats; high-shortage-risk care; chronic illness; and military readiness.
- The government must study the supply chains for every medicine on the list. The review must cover raw materials, inactive ingredients, factory locations, and reliance on risky foreign suppliers or foreign entities of concern.
- The review must find risks to public health and national security. It must include cyber threats and explain how existing powers, including the Defense Production Act, could reduce those risks.
- The government must send a written risk report to Congress and the Director of National Intelligence. The first report is due within 180 days after enactment, yearly reports follow, and a public version is due within one year.
How Modern Action helps you take action on S. 1784
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
Questions people ask about S. 1784
- What is S. 1784?
- The bill would make the government map supply chains for key medicines. Agencies would look for shortage risks, foreign dependence, cyber threats, and drugs tied to China. Congress would get regular reports, and the public would get some results.
- How do I support or oppose S. 1784?
- Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.
- Who should I contact about S. 1784?
- Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.
- Can Modern Action explain S. 1784 before I act?
- Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.
